Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology

Rhea-AI Summary

Treace Medical Concepts (NASDAQ: TMCI), a medical technology company specializing in bunion and midfoot deformity surgical treatments, has filed a patent infringement lawsuit against Zimmer Biomet Holdings and Paragon 28 (NYSE: ZBH). The lawsuit, filed in the U.S. District Court for the District of Delaware, alleges infringement of 4 patents related to Treace's Lapiplasty® 3D Bunion Correction® technologies. The company is seeking injunctive relief and damages. Treace's intellectual property portfolio consists of 80 U.S. patents, 26 international patents, and over 150 pending patent applications. CEO John T. Treace emphasized the company's position as the first to develop an instrumented 3D bunion correction system and stated the lawsuit aims to protect their research investments and stockholders' interests.

Positive

• Strong intellectual property portfolio with 106 granted patents globally and 150+ pending applications
• Company is proactively defending its market position and technological innovations
• First-mover advantage in 3D bunion correction system technology

Negative

• Legal expenses and resources required for patent litigation could impact financial performance
• Potential competitive pressure from larger medical device company Zimmer Biomet
• Uncertainty of litigation outcome and timeline

News Market Reaction – TMCI

%

1 alert

% News Effect

On the day this news was published, TMCI declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty^® and Adductoplasty^® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to Treace’s innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages.

“Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,” said John T. Treace, Chairman, CEO and Founder of Treace. “Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.”

Treace’s patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications. 

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

FAQ

What is the patent infringement lawsuit filed by Treace Medical (TMCI) about?

Treace Medical filed a lawsuit against Zimmer Biomet and Paragon 28 for alleged infringement of 4 patents related to their Lapiplasty® 3D Bunion Correction® technologies, seeking injunctive relief and damages.

How many patents does Treace Medical (TMCI) currently hold?

Treace Medical holds 80 granted U.S. patents, 26 granted international patents, and has over 150 pending patent applications.

Where was the TMCI patent lawsuit against Zimmer Biomet filed?

The lawsuit was filed in the United States District Court for the District of Delaware.

What is Treace Medical's (TMCI) main product technology?

Treace Medical's flagship technologies are the Lapiplasty® and Adductoplasty® procedures for surgical treatment of bunions and related midfoot deformities.

Who is the CEO of Treace Medical Concepts (TMCI)?

John T. Treace serves as the Chairman, CEO and Founder of Treace Medical Concepts.